ABT Aqua Bio Technology

Aqua Bio Technology Asa: Exercise Period Ending on 1 September 2019

Aqua Bio Technology Asa: Exercise Period Ending on 1 September 2019

Reference is made to the stock exchange notice of Aqua Bio Technology ASA ("ABT" or the "Company") published on 14 February 2019, regarding independent subscription rights issued by the Company ("Warrants").

The exercise period for the Warrants ends on 1 September 2019, and exercise notices may be received by the Company until the end of that date. Warrants that are not exercised within the end of 1 September 2019 will lapse automatically without compensation to the holder.

Each Warrant gives the holder a right to subscribe for one (1) share in the Company at a subscription price of NOK 2.50 per share. 

Holders of Warrants who wish to exercise these may do so by providing written notice to the Company, on the following address:

Aqua Bio Technology ASA

Fornebuveien 37

1366 Lysaker

Norway

E-mail:

Investors who require issuance of shares through exercise of Warrants shall receive these as effectively as practically possible after 1 September 2019. The Company will provide payment information for share deposits following exercise of Warrants.

For further information, please contact Edvard Cock, Chairman of the Board, telephone or

Aqua Bio Technology (ABT) is developing and commercializing sustainable biotechnology for use in skin care products. ABT's cosmetics ingredients are highly effective and they provide the cosmetics industry with natural alternatives to traditional ingredients. ABT is also marketing and distributing natural skin care products developed by partners towards consumers and professional users. Aqua Bio Technology is listed on the Axess market of the Oslo Stock Exchange.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.



EN
30/08/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aqua Bio Technology

 PRESS RELEASE

Aqua Bio Technology ASA: Safety studies of 6 products from the product...

Aqua Bio Technology ASA: Safety studies of 6 products from the product series Balance & Vitality completed and approved Aqua Bio Technology ASA: Safety studies of 6 products from the product series Balance & Vitality completed and approvedReference is made to the stock exchange announcement of regarding ongoing safety studies for the Nordic Beauty and Balance & Vitality product series. We have today received confirmation that the first 6 products from Balance & Vitality have passed the safety studies that the EU requires to be carried out before commercialization. The results for further 1...

 PRESS RELEASE

Aqua Bio Technology ASA: Sikkerhetsstudier av 6 produkter fra produkts...

Aqua Bio Technology ASA: Sikkerhetsstudier av 6 produkter fra produktserien Balance & Vitality fullført og godkjent Det vises til børsmelding av vedrørende pågående sikkerhetsstudier for produktseriene Nordic Beauty og Balance & Vitality. ABT har mottatt bekreftelse på at de 6 første produktene fra Balance & Vitality serien har passert sikkerhetsstudier som EU krever gjennomført før kommersialisering. Resultatene for ytterligere 18 produkter forventes i løpet av januar i 2021, mens de siste 3 produktene som kompletterer serien forventes godkjent i løpet av Q1. Balance & Vitality vil være e...

 PRESS RELEASE

Aqua Bio Technology ASA: Hydrafacial has entered into partnership with...

Aqua Bio Technology ASA: Hydrafacial has entered into partnership with Restorsea - Conversion Lab launches Veritas MD platform Restorsea's commercialization of Aqua Bio Technologies ASA's hatching fluid ingredient (Aquabeautine XL) continues. As mentioned in the commercial update on November 26, 2020, Restorsea has recently entered into two license agreements with two partners in addition to the license agreement with NASDAQ-listed Conversion Labs. In connection with Hydrafacial`s merger with Vesper Healthcare and the contemplated listing on (NASDAQ), Restorsea is presented as . In Q3 20...

 PRESS RELEASE

Aqua Bio Technology ASA: Hydrafacial har inngått samarbeid med Restors...

Aqua Bio Technology ASA: Hydrafacial har inngått samarbeid med Restorsea – Conversion Lab lanserer Veritas MD plattform Restorseas kommersialisering av Aqua Bio Technologys ASAs klekkeveskeingrediens (Aquabeautine XL) fortsetter. Som nevnt i kommersiell oppdatering 26. november 2020, har Restorsea nylig inngått to lisensavtaler med to partnere i tillegg til lisensavtalen med NASDAQ-noterte Conversion Labs. I forbindelse med Hydrafacial`s fusjon med Vesper Healthcare og den planlagte noteringen på (NASDAQ), presenteres Restorsea som . Hydrafacial opplyser at selskapet per Q3 2020 har utpl...

 PRESS RELEASE

Aqua Bio Technology ASA: Acquisition of Moana Skincare completed - dis...

Aqua Bio Technology ASA: Acquisition of Moana Skincare completed - distribution agreement for New Zealand and Australia close Reference is made to where it is informed that Aqua Bio Technology ASA (ABT) is acquiring all rights to Moana Skincare . This acquisition has now been completed and in the near future ABT expects to enter into a three-year agreement for the distribution of Moana products in New Zealand and Australia. Moana Skincare currently consists of a portfolio of 19 skin care products, most of which are based on potent extracts from plants found in New Zealand's unspoiled na...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch